Colorectal Cancer — An Interview with Dr John Strickler on Molecular Residual Disease Analysis (Companion Faculty Lecture)
Update: 2025-10-29
Description
Featuring a slide presentation and related discussion from Dr John Strickler, including the following topics:
- Defining molecular residual disease (MRD); tumor-informed and tumor-naïve methods for assessing (0:00 )
- GALAXY and BESPOKE CRC studies of a tumor-informed MRD assay to identify patients with localized colorectal cancer who have an increased risk of recurrence and those who are likely to benefit from adjuvant chemotherapy (6:56 )
- Sustained circulating tumor DNA (ctDNA) clearance and disease-free survival outcomes for patients with localized colorectal cancer (13:21 )
- DYNAMIC study of a ctDNA-guided approach to adjuvant chemotherapy for patients with Stage II colorectal cancer (16:17 )
- ctDNA positivity and radiographic evidence of colorectal cancer (18:48 )
- ctDNA-guided approaches to escalating or de-escalating adjuvant chemotherapy for patients with localized colorectal cancer (21:24 )
- Predictive role of ctDNA assay results in Stage III colon cancer treated with celecoxib; low-dose aspirin for patients with Stage II to III colorectal cancer with a PI3K pathway alteration (26:02 )
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
